---
title: "HFSA 2024: Aficamten shows improvement in clinical markers used to inform HCM care"
date: "2024-10-01T09:20:18.000Z"
publishedDate: "1 octobre 2024"
summary: "Cytokinetics has announced that additional analyses synthesizing data from SEQUOIA-HCM, the pivotal phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). The data were presented by Martin Maron (Lahey Hospital and Medical Center, Burlington, USA) as part of the Heart Failure Society of America (HFSA) annual scientific meeting."
importance: ""
sourceUrl: "https://cardiovascularnews.com/aficamten-improvement-clinical-markers-hcm/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2024-10-01-hfsa-2024-aficamten-shows-improvement-in-clinical-markers-used-to-inform-hcm-care"
imageUrl: "https://cardiovascularnews.com/wp-content/uploads/sites/14/2024/01/Medical-students-1024x768-1.jpeg"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/aficamten-improvement-clinical-markers-hcm/"
---

![HFSA 2024: Aficamten shows improvement in clinical markers used to inform HCM care](https://cardiovascularnews.com/wp-content/uploads/sites/14/2024/01/Medical-students-1024x768-1.jpeg)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/aficamten-improvement-clinical-markers-hcm/*

## L’essentiel

Cytokinetics has announced that additional analyses synthesizing data from SEQUOIA-HCM, the pivotal phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). The data were presented by Martin Maron (Lahey Hospital and Medical Center, Burlington, USA) as part of the Heart Failure Society of America (HFSA) annual scientific meeting.

## Lien source

https://cardiovascularnews.com/aficamten-improvement-clinical-markers-hcm/
